Acadia Pharmaceuticals Inc’s recently made public that its CEO DAVIS STEPHEN unloaded Company’s shares for reported $0.47 million on Apr 08 ’24. In the deal valued at $17.87 per share,26,574 shares were sold. As a result of this transaction, DAVIS STEPHEN now holds 144,267 shares worth roughly $2.47 million.
Then, Schneyer Mark C. sold 2,716 shares, generating $48,535 in total proceeds. Upon selling the shares at $17.87, the EVP, CHIEF FINANCIAL OFFICER now owns 28,742 shares.
Before that, Teehan Brendan sold 2,568 shares. Acadia Pharmaceuticals Inc shares valued at $45,890 were divested by the EVP, COO, HEAD OF COMMERCIAL at a price of $17.87 per share. As a result of the transaction, Teehan Brendan now holds 38,796 shares, worth roughly $0.66 million.
Needham reiterated its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy in a research note published on March 12, 2024; the price target was $32. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid March from “a Buy” to “a Neutral”. Robert W. Baird began covering ACAD with “an Outperform” recommendation on January 30, 2024. Needham revised its rating on January 24, 2024. It rated ACAD as “a Buy” which previously was an “a Hold”.
Price Performance Review of ACAD
On Friday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -1.55% to $17.14. Over the last five days, the stock has lost -4.83%. Acadia Pharmaceuticals Inc shares have fallen nearly -45.26% since the year began. Nevertheless, the stocks have fallen -6.54% over the past one year. While a 52-week high of $33.99 was reached on 01/02/24, a 52-week low of $17.34 was recorded on 04/12/24. SMA at 50 days reached $21.85, while 200 days put it at $24.89. A total of 1.3 million shares were traded, compared to the trading of 1.52 million shares in the previous session.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 16.79, which if violated will result in even more drops to 16.44. On the upside, there is a resistance level at 17.55. A further resistance level may holdings at 17.97. The Relative Strength Index (RSI) on the 14-day chart is 27.56, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.71%. Stochastics %K at 11.39% indicates the stock is a buying.
